Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Efficient apoptosis requires feedback amplification of upstream apoptotic signals by effector caspase-3 or -7.

McComb S, Chan PK, Guinot A, Hartmannsdottir H, Jenni S, Dobay MP, Bourquin JP, Bornhauser BC.

Sci Adv. 2019 Jul 31;5(7):eaau9433. doi: 10.1126/sciadv.aau9433. eCollection 2019 Jul.

2.

Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling.

Seyfried F, Demir S, Hörl RL, Stirnweiß FU, Ryan J, Scheffold A, Villalobos-Ortiz M, Boldrin E, Zinngrebe J, Enzenmüller S, Jenni S, Tsai YC, Bornhauser B, Fürstberger A, Kraus JM, Kestler HA, Bourquin JP, Stilgenbauer S, Letai A, Debatin KM, Meyer LH.

Cell Death Dis. 2019 Jul 29;10(8):571. doi: 10.1038/s41419-019-1801-0.

3.

Reduction of Nanoparticle Load in Cells by Mitosis but Not Exocytosis.

Bourquin J, Septiadi D, Vanhecke D, Balog S, Steinmetz L, Spuch-Calvar M, Taladriz-Blanco P, Petri-Fink A, Rothen-Rutishauser B.

ACS Nano. 2019 Jul 23;13(7):7759-7770. doi: 10.1021/acsnano.9b01604. Epub 2019 Jul 11.

PMID:
31276366
4.

γ-Catenin-Dependent Signals Maintain BCR-ABL1+ B Cell Acute Lymphoblastic Leukemia.

Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, Irmisch A, Curtet S, Angelov GS, Danilo M, Juilland M, Bornhauser B, Thome M, Hantschel O, Chalandon Y, Cazzaniga G, Bourquin JP, Huelsken J, Held W.

Cancer Cell. 2019 Apr 15;35(4):649-663.e10. doi: 10.1016/j.ccell.2019.03.005.

PMID:
30991025
5.

Correction: Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR.

Leukemia. 2019 Apr;33(4):1061-1062. doi: 10.1038/s41375-019-0426-8.

PMID:
30842605
6.

Artificial Lysosomal Platform to Study Nanoparticle Long-term Stability.

MilosevicAc A, Bourquin J, Burnand D, Lemal P, Crippa F, Monnier CA, Rodriguez-Lorenzo L, Petri-Fink A, Rothen-Rutishauser B.

Chimia (Aarau). 2019 Feb 27;73(1):55-58. doi: 10.2533/chimia.2019.55.

PMID:
30813999
7.

Durable remissions in TCF3-HLF positive acute lymphoblastic leukemia with blinatumomab and stem cell transplantation.

Mouttet B, Vinti L, Ancliff P, Bodmer N, Brethon B, Cario G, Chen-Santel C, Elitzur S, Hazar V, Kunz J, Möricke A, Stein J, Vora A, Yaman Y, Schrappe M, Anak S, Baruche A, Locatelli F, von Stackelberg A, Stanulla M, Bourquin JP.

Haematologica. 2019 Jun;104(6):e244-e247. doi: 10.3324/haematol.2018.210104. Epub 2019 Feb 14. No abstract available.

8.

CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia.

Schinnerl D, Mejstrikova E, Schumich A, Zaliova M, Fortschegger K, Nebral K, Attarbaschi A, Fiser K, Kauer MO, Popitsch N, Haslinger S, Inthal A, Buldini B, Basso G, Bourquin JP, Gaipa G, Brüggemann M, Feuerstein T, Maurer-Granofszky M, Panzer-Grümayer R, Trka J, Mann G, Haas OA, Hrusak O, Dworzak MN, Strehl S.

Haematologica. 2019 Aug;104(8):e352-e355. doi: 10.3324/haematol.2018.214353. Epub 2019 Jan 31. No abstract available.

9.

Sub-picomolar quantification of PTH 1-34 in plasma by UHPLC-MS/MS after subcutaneous injection of teriparatide and identification of PTH 1-33, its degradation product.

Eugster PJ, Chtioui H, Herren A, Dunand M, Cappelle D, Bourquin J, Buclin T, Grouzmann E.

J Pharm Biomed Anal. 2019 Mar 20;166:205-212. doi: 10.1016/j.jpba.2019.01.011. Epub 2019 Jan 9.

PMID:
30660035
10.

PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia.

Richter-Pechańska P, Kunz JB, Bornhauser B, von Knebel Doeberitz C, Rausch T, Erarslan-Uysal B, Assenov Y, Frismantas V, Marovca B, Waszak SM, Zimmermann M, Seemann J, Happich M, Stanulla M, Schrappe M, Cario G, Escherich G, Bakharevich K, Kirschner-Schwabe R, Eckert C, Muckenthaler MU, Korbel JO, Bourquin JP, Kulozik AE.

EMBO Mol Med. 2018 Dec;10(12). pii: e9443. doi: 10.15252/emmm.201809443.

11.

Revealing the Role of Epithelial Mechanics and Macrophage Clearance during Pulmonary Epithelial Injury Recovery in the Presence of Carbon Nanotubes.

Septiadi D, Abdussalam W, Rodriguez-Lorenzo L, Spuch-Calvar M, Bourquin J, Petri-Fink A, Rothen-Rutishauser B.

Adv Mater. 2018 Dec;30(52):e1806181. doi: 10.1002/adma.201806181. Epub 2018 Oct 29.

PMID:
30370701
12.

Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR.

Leukemia. 2019 Apr;33(4):884-892. doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28. Erratum in: Leukemia. 2019 Mar 7;:.

13.

New Approaches to the Management of Adult Acute Lymphoblastic Leukemia.

Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S.

J Clin Oncol. 2018 Sep 21:JCO2017773648. doi: 10.1200/JCO.2017.77.3648. [Epub ahead of print]

PMID:
30240326
14.

USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.

Jin Q, Martinez CA, Arcipowski KM, Zhu Y, Gutierrez-Diaz BT, Wang KK, Johnson MR, Volk AG, Wang F, Wu J, Grove C, Wang H, Sokirniy I, Thomas PM, Goo YA, Abshiru NA, Hijiya N, Peirs S, Vandamme N, Berx G, Goosens S, Marshall SA, Rendleman EJ, Takahashi YH, Wang L, Rawat R, Bartom ET, Collings CK, Van Vlierberghe P, Strikoudis A, Kelly S, Ueberheide B, Mantis C, Kandela I, Bourquin JP, Bornhauser B, Serafin V, Bresolin S, Paganin M, Accordi B, Basso G, Kelleher NL, Weinstock J, Kumar S, Crispino JD, Shilatifard A, Ntziachristos P.

Clin Cancer Res. 2019 Jan 1;25(1):222-239. doi: 10.1158/1078-0432.CCR-18-1740. Epub 2018 Sep 17.

PMID:
30224337
15.

Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia.

Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, Vandepoel R, Geerdens E, Radaelli E, Bornhauser BC, Kulozik AE, Meijerink JP, Bourquin JP, de Bock CE, Cools J.

Cancer Cell. 2018 Aug 13;34(2):271-285.e7. doi: 10.1016/j.ccell.2018.07.007.

16.

Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group.

Niktoreh N, Lerius B, Zimmermann M, Gruhn B, Escherich G, Bourquin JP, Dworzak M, Sramkova L, Rossig C, Creutzig U, Reinhardt D, Rasche M.

Haematologica. 2019 Jan;104(1):120-127. doi: 10.3324/haematol.2018.191841. Epub 2018 Aug 9.

17.

Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma.

De Smedt R, Peirs S, Morscio J, Matthijssens F, Roels J, Reunes L, Lintermans B, Goossens S, Lammens T, Van Roy N, Touzart A, Jenni S, Tsai YC, Lovisa F, Mussolin L, Serafin V, Van Nieuwerburgh F, Deforce D, Uyttebroeck A, Tousseyn T, Burkhardt B, Klapper W, De Moerloose B, Benoit Y, Macintyre E, Bourquin JP, Basso G, Accordi B, Bornhauser B, Meijerink J, Vandenberghe P, Van Vlierberghe P.

Haematologica. 2019 Jan;104(1):e17-e20. doi: 10.3324/haematol.2018.199257. Epub 2018 Aug 3. No abstract available.

18.

A novel sample holder for 4D live cell imaging to study cellular dynamics in complex 3D tissue cultures.

Septiadi D, Bourquin J, Durantie E, Petri-Fink A, Rothen-Rutishauser B.

Sci Rep. 2018 Jun 29;8(1):9861. doi: 10.1038/s41598-018-28206-2.

19.

Postnatal changes in epigenetic modifications of neutrophils of foals are associated with increased ROS function and regulation of neutrophil function.

Dindot SV, Doan RN, Kuskie KR, Hillman PR, Whitfield CM, McQueen CM, Bordin AI, Bourquin JR, Cohen ND.

Dev Comp Immunol. 2018 Oct;87:182-187. doi: 10.1016/j.dci.2018.06.012. Epub 2018 Jun 26.

PMID:
29958850
20.

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies.

Place AE, Goldsmith K, Bourquin JP, Loh ML, Gore L, Morgenstern DA, Sanzgiri Y, Hoffman D, Zhou Y, Ross JA, Prine B, Shebley M, McNamee M, Farazi T, Kim SY, Verdugo M, Lash-Fleming L, Zwaan CM, Vormoor J.

Future Oncol. 2018 Sep;14(21):2115-2129. doi: 10.2217/fon-2018-0121. Epub 2018 Mar 29.

21.

Successes and challenges in the treatment of pediatric acute myeloid leukemia: a retrospective analysis of the AML-BFM trials from 1987 to 2012.

Rasche M, Zimmermann M, Borschel L, Bourquin JP, Dworzak M, Klingebiel T, Lehrnbecher T, Creutzig U, Klusmann JH, Reinhardt D.

Leukemia. 2018 Oct;32(10):2167-2177. doi: 10.1038/s41375-018-0071-7. Epub 2018 Feb 22.

22.

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia.

Stanulla M, Dagdan E, Zaliova M, Möricke A, Palmi C, Cazzaniga G, Eckert C, Te Kronnie G, Bourquin JP, Bornhauser B, Koehler R, Bartram CR, Ludwig WD, Bleckmann K, Groeneveld-Krentz S, Schewe D, Junk SV, Hinze L, Klein N, Kratz CP, Biondi A, Borkhardt A, Kulozik A, Muckenthaler MU, Basso G, Valsecchi MG, Izraeli S, Petersen BS, Franke A, Dörge P, Steinemann D, Haas OA, Panzer-Grümayer R, Cavé H, Houlston RS, Cario G, Schrappe M, Zimmermann M; TRANSCALL Consortium; International BFM Study Group.

J Clin Oncol. 2018 Apr 20;36(12):1240-1249. doi: 10.1200/JCO.2017.74.3617. Epub 2018 Mar 2.

PMID:
29498923
23.

Evaluation of cAMS for 14C microtracer ADME studies: opportunities to change the current drug development paradigm.

Lozac'h F, Fahrni S, Maria D, Welte C, Bourquin J, Synal HA, Pearson D, Walles M, Camenisch G.

Bioanalysis. 2018 Mar 1;10(5):321-339. doi: 10.4155/bio-2017-0216. Epub 2018 Feb 16.

24.

Biodistribution, Clearance, and Long-Term Fate of Clinically Relevant Nanomaterials.

Bourquin J, Milosevic A, Hauser D, Lehner R, Blank F, Petri-Fink A, Rothen-Rutishauser B.

Adv Mater. 2018 May;30(19):e1704307. doi: 10.1002/adma.201704307. Epub 2018 Feb 1. Review.

PMID:
29389049
25.

CRISPR/Cas9-edited NSG mice as PDX models of human leukemia to address the role of niche-derived SPARC.

Tirado-Gonzalez I, Czlonka E, Nevmerzhitskaya A, Soetopo D, Bergonzani E, Mahmoud A, Contreras A, Jeremias I, Platzbecker U, Bourquin JP, Kloz U, Van der Hoeven F, Medyouf H.

Leukemia. 2018 Apr;32(4):1049-1052. doi: 10.1038/leu.2017.346. Epub 2017 Dec 6. No abstract available.

PMID:
29209043
26.

Biodistribution of single and aggregated gold nanoparticles exposed to the human lung epithelial tissue barrier at the air-liquid interface.

Durantie E, Vanhecke D, Rodriguez-Lorenzo L, Delhaes F, Balog S, Septiadi D, Bourquin J, Petri-Fink A, Rothen-Rutishauser B.

Part Fibre Toxicol. 2017 Nov 29;14(1):49. doi: 10.1186/s12989-017-0231-3.

27.

A precision medicine approach to haematological malignancies.

Bourquin JP.

Lancet Haematol. 2017 Dec;4(12):e567-e568. doi: 10.1016/S2352-3026(17)30213-2. Epub 2017 Nov 15. No abstract available.

28.

Humanised mouse models for haematopoiesis and infectious diseases.

Lysenko V, McHugh D, Behrmann L, Rochat MA, Wilk CM, Kovtonyuk L, Bourquin JP, Münz C, Manz MG, Speck R, Theocharides A.

Swiss Med Wkly. 2017 Oct 22;147:w14516. doi: 10.4414/smw.2017.14516. eCollection 2017. Review.

29.

RNA interference efficiently targets human leukemia driven by a fusion oncogene in vivo.

Jyotsana N, Sharma A, Chaturvedi A, Scherr M, Kuchenbauer F, Sajti L, Barchanski A, Lindner R, Noyan F, Sühs KW, Grote-Koska D, Brand K, Vornlocher HP, Stanulla M, Bornhauser B, Bourquin JP, Eder M, Thol F, Ganser A, Humphries RK, Ramsay E, Cullis P, Heuser M.

Leukemia. 2018 Jan;32(1):224-226. doi: 10.1038/leu.2017.269. Epub 2017 Aug 22. No abstract available.

30.

Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.

Ceppi F, Beck-Popovic M, Bourquin JP, Renella R.

Eur J Pediatr. 2017 Sep;176(9):1163-1172. doi: 10.1007/s00431-017-2982-0. Epub 2017 Aug 12. Review.

PMID:
28803259
31.

From class waivers to precision medicine in paediatric oncology.

Pearson ADJ, Pfister SM, Baruchel A, Bourquin JP, Casanova M, Chesler L, Doz F, Eggert A, Geoerger B, Jones DTW, Kearns PR, Molenaar JJ, Morland B, Schleiermacher G, Schulte JH, Vormoor J, Marshall LV, Zwaan CM, Vassal G; Executive and Biology Committees of the Innovative Therapies for Children with Cancer European Consortium.

Lancet Oncol. 2017 Jul;18(7):e394-e404. doi: 10.1016/S1470-2045(17)30442-4. Review.

PMID:
28677575
32.

Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups.

Creutzig U, Dworzak MN, Zimmermann M, Reinhardt D, Sramkova L, Bourquin JP, Hasle H, Abrahamsson J, Kaspers G, van den Heuvel MM, Reedijk AMJ, De Moerloose B, Locatelli F, Masetti R.

Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26664. Epub 2017 Jun 9.

PMID:
28598536
33.

CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

Al Sayed MF, Ruckstuhl CA, Hilmenyuk T, Claus C, Bourquin JP, Bornhauser BC, Radpour R, Riether C, Ochsenbein AF.

Blood. 2017 Jul 20;130(3):297-309. doi: 10.1182/blood-2016-12-756585. Epub 2017 May 11.

PMID:
28495792
34.

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.

Rasche M, von Neuhoff C, Dworzak M, Bourquin JP, Bradtke J, Göhring G, Escherich G, Fleischhack G, Graf N, Gruhn B, Haas OA, Klingebiel T, Kremens B, Lehrnbecher T, von Stackelberg A, Tchinda J, Zemanova Z, Thiede C, von Neuhoff N, Zimmermann M, Creutzig U, Reinhardt D.

Leukemia. 2017 Dec;31(12):2807-2814. doi: 10.1038/leu.2017.121. Epub 2017 Apr 25.

35.

Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemia.

McGinn OJ, Krishnan S, Bourquin JP, Sapra P, Dempsey C, Saha V, Stern PL.

Haematologica. 2017 Jun;102(6):1075-1084. doi: 10.3324/haematol.2016.158485. Epub 2017 Mar 24.

36.

AIEOP-BFM consensus guidelines 2016 for flow cytometric immunophenotyping of Pediatric acute lymphoblastic leukemia.

Dworzak MN, Buldini B, Gaipa G, Ratei R, Hrusak O, Luria D, Rosenthal E, Bourquin JP, Sartor M, Schumich A, Karawajew L, Mejstrikova E, Maglia O, Mann G, Ludwig WD, Biondi A, Schrappe M, Basso G; International-BFM-FLOW-network.

Cytometry B Clin Cytom. 2018 Jan;94(1):82-93. doi: 10.1002/cyto.b.21518. Epub 2017 Feb 21.

37.

Infection as a cause of childhood leukemia: virus detection employing whole genome sequencing.

Bartenhagen C, Fischer U, Korn K, Pfister SM, Gombert M, Chen C, Okpanyi V, Hauer J, Rinaldi A, Bourquin JP, Eckert C, Hu J, Ensser A, Dugas M, Borkhardt A.

Haematologica. 2017 May;102(5):e179-e183. doi: 10.3324/haematol.2016.155382. Epub 2017 Feb 2. No abstract available.

38.

Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.

Frismantas V, Dobay MP, Rinaldi A, Tchinda J, Dunn SH, Kunz J, Richter-Pechanska P, Marovca B, Pail O, Jenni S, Diaz-Flores E, Chang BH, Brown TJ, Collins RH, Uhrig S, Balasubramanian GP, Bandapalli OR, Higi S, Eugster S, Voegeli P, Delorenzi M, Cario G, Loh ML, Schrappe M, Stanulla M, Kulozik AE, Muckenthaler MU, Saha V, Irving JA, Meisel R, Radimerski T, Von Stackelberg A, Eckert C, Tyner JW, Horvath P, Bornhauser BC, Bourquin JP.

Blood. 2017 Mar 16;129(11):e26-e37. doi: 10.1182/blood-2016-09-738070. Epub 2017 Jan 25.

39.

Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.

Peirs S, Frismantas V, Matthijssens F, Van Loocke W, Pieters T, Vandamme N, Lintermans B, Dobay MP, Berx G, Poppe B, Goossens S, Bornhauser BC, Bourquin JP, Van Vlierberghe P.

Leukemia. 2017 Oct;31(10):2037-2047. doi: 10.1038/leu.2017.10. Epub 2017 Jan 11.

40.

Transcriptome-wide identification of NMD-targeted human mRNAs reveals extensive redundancy between SMG6- and SMG7-mediated degradation pathways.

Colombo M, Karousis ED, Bourquin J, Bruggmann R, Mühlemann O.

RNA. 2017 Feb;23(2):189-201. doi: 10.1261/rna.059055.116. Epub 2016 Nov 18.

41.

Complementary activities of DOT1L and Menin inhibitors in MLL-rearranged leukemia.

Dafflon C, Craig VJ, Méreau H, Gräsel J, Schacher Engstler B, Hoffman G, Nigsch F, Gaulis S, Barys L, Ito M, Aguadé-Gorgorió J, Bornhauser B, Bourquin JP, Proske A, Stork-Fux C, Murakami M, Sellers WR, Hofmann F, Schwaller J, Tiedt R.

Leukemia. 2017 Jun;31(6):1269-1277. doi: 10.1038/leu.2016.327. Epub 2016 Nov 14.

PMID:
27840424
42.

Activation of concurrent apoptosis and necroptosis by SMAC mimetics for the treatment of refractory and relapsed ALL.

McComb S, Aguadé-Gorgorió J, Harder L, Marovca B, Cario G, Eckert C, Schrappe M, Stanulla M, von Stackelberg A, Bourquin JP, Bornhauser BC.

Sci Transl Med. 2016 May 18;8(339):339ra70. doi: 10.1126/scitranslmed.aad2986.

PMID:
27194728
43.

Resistance Exercise Attenuates High-Fructose, High-Fat-Induced Postprandial Lipemia.

Wilburn JR, Bourquin J, Wysong A, Melby CL.

Nutr Metab Insights. 2015 Oct 14;8:29-35. doi: 10.4137/NMI.S32106. eCollection 2015.

44.

Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.

Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz HJ, Bornhauser B, Gombert M, Kratsch C, Stütz AM, Sultan M, Tchinda J, Worth CL, Amstislavskiy V, Badarinarayan N, Baruchel A, Bartram T, Basso G, Canpolat C, Cario G, Cavé H, Dakaj D, Delorenzi M, Dobay MP, Eckert C, Ellinghaus E, Eugster S, Frismantas V, Ginzel S, Haas OA, Heidenreich O, Hemmrich-Stanisak G, Hezaveh K, Höll JI, Hornhardt S, Husemann P, Kachroo P, Kratz CP, Te Kronnie G, Marovca B, Niggli F, McHardy AC, Moorman AV, Panzer-Grümayer R, Petersen BS, Raeder B, Ralser M, Rosenstiel P, Schäfer D, Schrappe M, Schreiber S, Schütte M, Stade B, Thiele R, von der Weid N, Vora A, Zaliova M, Zhang L, Zichner T, Zimmermann M, Lehrach H, Borkhardt A, Bourquin JP, Franke A, Korbel JO, Stanulla M, Yaspo ML.

Nat Genet. 2015 Sep;47(9):1020-1029. doi: 10.1038/ng.3362. Epub 2015 Jul 27.

45.

Reprogramming of B cell acute lymphoblastic leukemia cells: Do we need to shoot a moving target?

Fišer K, Slámová L, Bourquin JP, Trka J, Starý J, Hrušák O, Mejstříková E.

Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):E3455. doi: 10.1073/pnas.1508680112. Epub 2015 Jun 11. No abstract available.

46.

Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.

Creutzig U, Dworzak M, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, von Stackelberg A, Stray J, Reinhardt D.

Klin Padiatr. 2015 May;227(3):116-22. doi: 10.1055/s-0035-1548816. Epub 2015 May 18.

PMID:
25985446
47.

A mass spectrometric-derived cell surface protein atlas.

Bausch-Fluck D, Hofmann A, Bock T, Frei AP, Cerciello F, Jacobs A, Moest H, Omasits U, Gundry RL, Yoon C, Schiess R, Schmidt A, Mirkowska P, Härtlová A, Van Eyk JE, Bourquin JP, Aebersold R, Boheler KR, Zandstra P, Wollscheid B.

PLoS One. 2015 Apr 20;10(3):e0121314. doi: 10.1371/journal.pone.0121314. eCollection 2015.

48.

Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.

Creutzig U, Dworzak MN, Zimmermann M, Bourquin JP, Gruhn B, Fleischhack G, Graf N, Klingebiel T, Kremens B, Lehrnbecher T, von Neuhoff C, Stackelberg AV, Starý J, Reinhardt D.

Leukemia. 2015 Nov;29(11):2260-3. doi: 10.1038/leu.2015.94. Epub 2015 Apr 14. No abstract available.

PMID:
25869725
49.

Fine tuning of surface CRLF2 expression and its associated signaling profile in childhood B-cell precursor acute lymphoblastic leukemia.

Bugarin C, Sarno J, Palmi C, Savino AM, te Kronnie G, Dworzak M, Shumich A, Buldini B, Maglia O, Sala S, Bronzini I, Bourquin JP, Mejstrikova E, Hrusak O, Luria D, Basso G, Izraeli S, Biondi A, Cazzaniga G, Gaipa G; I-BFM study group.

Haematologica. 2015 Jun;100(6):e229-32. doi: 10.3324/haematol.2014.114447. Epub 2015 Apr 10. No abstract available.

50.

Monitoring minimal residual disease in children with high-risk relapses of acute lymphoblastic leukemia: prognostic relevance of early and late assessment.

Eckert C, Hagedorn N, Sramkova L, Mann G, Panzer-Grümayer R, Peters C, Bourquin JP, Klingebiel T, Borkhardt A, Cario G, Alten J, Escherich G, Astrahantseff K, Seeger K, Henze G, von Stackelberg A.

Leukemia. 2015 Aug;29(8):1648-55. doi: 10.1038/leu.2015.59. Epub 2015 Mar 9.

PMID:
25748682

Supplemental Content

Loading ...
Support Center